Singapore’s GIC Private said that steps taken last year to de-risk its portfolio – reducing its allocation to equities in favor of cash and evaluating deals with more caution – have limited the negative impact of COVID-19.
Further, the sovereign wealth fund, which claims to have invested well over $100 billion while independent assessments put its wealth at more than $300 billion, expects its long-term outlook to pay off...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.